ReviewJournal of clinical medicine2020
Mast Cells, microRNAs and Others: The Role of Translational Research on Colorectal Cancer in the Forthcoming Era of Precision Medicine.
Review in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 58 citations in OpenAlex.
- Editorial: Advances in proctology and colorectal surgery, volume II.Frontiers in surgery · 2026Article
- Assessment of the Nutraceutical Properties of Wild Strawberry (Fragaria vesca L.) Extracts on Human Colorectal Cell Lines.Molecular nutrition & food research · 2025Article
- Review
- Article
- Oxidative Balance Score Calculated Using Different Methods and Its Associations with Colorectal Cancer Risk.Nutrients · 2025Article
- Minimally Invasive Rectal Surgery: Current Status and Future Perspectives in the Era of Digital Surgery.Journal of clinical medicine · 2025Review
- KRAS Mutation Status in Relation to Clinicopathological Characteristics of Romanian Colorectal Cancer Patients.Current issues in molecular biology · 2025Article
- Article
- Chemotherapy-Induced Changes in Plasma Amino Acids and Lipid Oxidation of Resected Patients with Colorectal Cancer: A Background for Future Studies.International journal of molecular sciences · 2024Article
- Article
- Editorial: Future frontiers in the management of metastatic colorectal cancer.Frontiers in oncology · 2024Article
- The Critical Function of microRNAs in Developing Resistance against 5- Fluorouracil in Cancer Cells.Mini reviews in medicinal chemistry · 2024Review
- Adjuvant Effect of Cinnamon Polyphenolic Components in Colorectal Cancer Cell Lines.International journal of molecular sciences · 2023Article
- Prognostic Potential of Nectin Expressions in Colorectal Cancer: An Exploratory Study.International journal of molecular sciences · 2023Article
- Single-Cell RNA Sequencing (scRNA-seq) Identifies L1CAM as a Key Mediator between Epithelial Tuft Cell and Innate Lymphoid Cell in the Colon ofBiomedicines · 2023Article
- Single-cell RNA-Seq and bulk RNA-Seq reveal reliable diagnostic and prognostic biomarkers for CRC.Journal of cancer research and clinical oncology · 2023Article
- The Significance of CXCL1 and CXCR1 as Potential Biomarkers of Colorectal Cancer.Biomedicines · 2023Article
- MicroRNAs-Based Theranostics against Anesthetic-Induced Neurotoxicity.Pharmaceutics · 2023Review
- Baseline Expression of Exosomal miR-92a-3p and miR-221-3p Could Predict the Response to First-Line Chemotherapy and Survival in Metastatic Colorectal Cancer.International journal of molecular sciences · 2023Article
- The Role of HECT E3 Ubiquitin Ligases in Colorectal Cancer.Biomedicines · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a heterogeneous disease, molecularly and anatomically, that develops in a multi-step process requiring the accumulation of several genetic or epigenetic mutations that lead to the gradual transformation of normal mucosa into cancer. In fact, tumorigenesis is extremely complex, with many immunologic and non-immunologic factors present in the tumor microenvironment that can influence tumorigenesis. In the last few years, a role for mast cells (MCs), microRNAs (miRNAs), Kirsten rat sarcoma (KRAS) and v-raf murine sarcoma viral oncogene homologue B (BRAF) in cancer development and progression has been suggested, and numerous efforts have been made to thoroughly assess their correlation with CRC to improve patient survival and quality of life. The identification of easily measurable, non-invasive and cost-effective biomarkers, the so-called "ideal biomarkers", for CRC screening and treatment remains a high priority. The aim of this review is to discuss the emerging role of mast cells (MCs), microRNAs (miRNAs), KRAS and BRAF as diagnostic and prognostic biomarkers for CRC, evaluating their influence as potential therapy targets in the forthcoming era of precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.